Patents by Inventor Steven Kultgen

Steven Kultgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230045421
    Abstract: The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat and/or prevent hepatitis B virus (HBV) infections in a patient.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 9, 2023
    Inventors: Andrew G. Cole, Yi Fan, Steven Kultgen, Eugen Mesaros
  • Substituted tetrahydrocyclopenta[C]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same
    Patent number: 11566002
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: January 31, 2023
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Steven Kultgen
  • Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
    Patent number: 11098010
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 24, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Ramesh Kakarla, Steven Kultgen, Jorge Quintero
  • SUBSTITUTED TETRAHYDROCYCLOPENTA[C]PYRROLES, SUBSTITUTED DIHYDROPYRROLIZINES, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20210179557
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.
    Type: Application
    Filed: July 25, 2019
    Publication date: June 17, 2021
    Inventors: Andrew G. COLE, Steven KULTGEN
  • Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
    Patent number: 11001564
    Abstract: The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 11, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Steven Kultgen
  • SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME
    Publication number: 20200024226
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 23, 2020
    Applicant: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Ramesh Kakarla, Steven Kultgen, Jorge Quintero
  • SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20190225593
    Abstract: The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 25, 2019
    Inventors: ANDREW G. COLE, STEVEN KULTGEN
  • Compounds with medicinal effects due to interaction with the glucocorticoid receptor
    Publication number: 20070149577
    Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicants: N.V. Organon, Pharmacopeia Drug Discovery Inc.
    Inventors: Niall Hamilton, Simon Grove, Michael Kiczun, John Morphy, Brad Sherborne, Peter Littlewood, Angus Brown, Celia Kingsbury, Michael Ohlmeyer, Koc-Kan Ho, Steven Kultgen